AU2010259284A1 - Use of a composition for the treatment of mucositis - Google Patents

Use of a composition for the treatment of mucositis Download PDF

Info

Publication number
AU2010259284A1
AU2010259284A1 AU2010259284A AU2010259284A AU2010259284A1 AU 2010259284 A1 AU2010259284 A1 AU 2010259284A1 AU 2010259284 A AU2010259284 A AU 2010259284A AU 2010259284 A AU2010259284 A AU 2010259284A AU 2010259284 A1 AU2010259284 A1 AU 2010259284A1
Authority
AU
Australia
Prior art keywords
composition
mucositis
chitosan
range
negatively charged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010259284A
Other languages
English (en)
Inventor
Lars Adolfsson
Olle Larm
Anders Westermark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EXTHERA AB
Original Assignee
EXTHERA AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EXTHERA AB filed Critical EXTHERA AB
Publication of AU2010259284A1 publication Critical patent/AU2010259284A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2010259284A 2009-06-10 2010-06-10 Use of a composition for the treatment of mucositis Abandoned AU2010259284A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0950441-6 2009-06-10
SE0950441 2009-06-10
PCT/SE2010/050650 WO2010144044A1 (en) 2009-06-10 2010-06-10 Use of a composition for the treatment of mucositis

Publications (1)

Publication Number Publication Date
AU2010259284A1 true AU2010259284A1 (en) 2011-12-15

Family

ID=43309105

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010259284A Abandoned AU2010259284A1 (en) 2009-06-10 2010-06-10 Use of a composition for the treatment of mucositis

Country Status (9)

Country Link
US (1) US8906883B2 (https=)
EP (1) EP2440216A4 (https=)
JP (1) JP2012529506A (https=)
CN (1) CN102458419A (https=)
AU (1) AU2010259284A1 (https=)
BR (1) BRPI1009741A2 (https=)
CA (1) CA2763092A1 (https=)
RU (1) RU2011152518A (https=)
WO (1) WO2010144044A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2795520C (en) 2010-04-06 2018-03-06 Synedgen Inc. Methods and compositions for treating wounds utilizing chitosan compounds
WO2014047506A1 (en) 2012-09-20 2014-03-27 Synedgen, Inc. Methods for treatment or prevention of damage resulting from radiation, trauma or shock
US20160193244A1 (en) * 2013-08-13 2016-07-07 Seikagaku Corporation Drug containing cationized chitosan
SG11201603081WA (en) * 2013-10-22 2016-05-30 Cantex Pharmaceuticals Inc Methods of treating and preventing radiation damage
US20180228832A1 (en) * 2015-08-18 2018-08-16 Pharma Seeds Create, Llc Stomatological composition containing nsaid or heparin compound
EP3787593A1 (en) * 2018-05-04 2021-03-10 Bonoss Medical Aktiebolag A composition for reduction of scar formation
WO2019236453A1 (en) 2018-06-03 2019-12-12 Glycomira Therapeutics, Inc. Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and /or chemotherapy
WO2021216494A1 (en) * 2020-04-24 2021-10-28 Intact Therapeutics, Inc. Compositions and methods for treatment of gastrointestinal bleeding
EP3981505B1 (en) * 2020-10-12 2024-11-27 Gambro Lundia AB Membrane with immobilized anticoagulant and process for producing same
SE545090C2 (en) * 2021-03-17 2023-03-28 Labrida As A hydrogel comprising chitosan for use in prevention and treatment of periodontal and peri-implant disease
EP4401784A4 (en) * 2021-09-17 2025-09-10 Shawn Walker USE OF CHITOSAN COMPLEXES OR COMPOSITIONS TO REDUCE THE INFILTRATION OF ENVIRONMENTAL FACTORS INTO THE BRAIN

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402531L (sv) * 1994-07-19 1996-01-20 Medicarb Ab Sårläkningsmedel
SE9402529D0 (sv) 1994-07-19 1994-07-19 Astra Ab Anti-adherensmedel
SE507028C2 (sv) 1996-08-06 1998-03-16 Medicarb Ab Ny medicinsk användning
US6989156B2 (en) 2001-04-23 2006-01-24 Nucryst Pharmaceuticals Corp. Therapeutic treatments using the direct application of antimicrobial metal compositions
DK1363600T3 (da) 2001-02-15 2009-01-26 Access Pharma Inc Flydende formuleringer til forebyggelse og behandling af mucosale sygdomme og lidelser
EP1539192A1 (en) * 2002-04-24 2005-06-15 Medicarb AB Composition and kit for the treatment of inflammatory bowel diseases
CA2501614A1 (en) * 2002-10-07 2004-04-22 Orapharma, Inc. Mucoadhesive tetracycline formulations
CA2581076A1 (en) * 2004-09-14 2006-03-23 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
EP1838335A1 (en) * 2005-01-19 2007-10-03 Bonoss Medical AB Growth factor composition
DE102006024831B4 (de) 2006-05-24 2008-03-27 Heraeus Quarzglas Gmbh & Co. Kg Verfahren zur Herstellung eines Halbzeugs aus synthetischem Quarzglas
WO2008060764A2 (en) 2006-10-05 2008-05-22 Drugtech Corporation Topical therapies for oral mucositis and other conditions

Also Published As

Publication number Publication date
BRPI1009741A2 (pt) 2016-03-15
US8906883B2 (en) 2014-12-09
WO2010144044A1 (en) 2010-12-16
CA2763092A1 (en) 2010-12-16
US20120077773A1 (en) 2012-03-29
EP2440216A1 (en) 2012-04-18
CN102458419A (zh) 2012-05-16
EP2440216A4 (en) 2013-09-11
JP2012529506A (ja) 2012-11-22
RU2011152518A (ru) 2013-07-20

Similar Documents

Publication Publication Date Title
US8906883B2 (en) Treatment of oral mucositis by administering an ionic complex of chitosan and a negatively charged polysaccharide selected from heparin, heparan sulfate and dextran sulfate
JP4354528B2 (ja) 間質性膀胱炎の治療へのヒアルロン酸の使用
JP4194653B2 (ja) アフタ口内潰瘍に伴う痛みの即効的解放のための薬剤組成物
EP2525803B1 (en) Antimicrobial agentcomprising peroxide, alcohol and chelating agent
RU2272636C2 (ru) Фармацевтическая композиция для местного лечения воспаления и способ ее изготовления
US20100144618A1 (en) Compositions containing an intestinal trefoil peptide and a mucoadhesive
US5972906A (en) Treatment of mucous membrane disease, trauma or condition and for the relief of pain thereof
AU694113B2 (en) Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
CA2152398A1 (en) Hyaluronic acid-urea pharmaceutical compositions and uses
WO2007005720A2 (en) Methods and compositions for promoting wound healing
HU228669B1 (en) Pharmaceutical compositions for the treatment of painful, inflammatory and ulcerative conditions of moist epithelial surfaces such as mucositis, stomatitis and behcet's syndrome
JP4685242B2 (ja) ヒアルロン酸を用いた放射線膀胱炎の予防、軽減、および治療法
Koshariya et al. Role of topical Sucralfate in healing of burn wounds
JP2018538315A (ja) 骨関節炎治療のための親水化されたスルファサラジンおよびヒアルロン酸を含む組成物およびその製造方法
EP1351694B1 (fr) Favorisation de la reconstruction cellulaire et/ou de la differenciation cellulaire avec sucre non metabolisable et un absorbant polymerique
RU2258516C1 (ru) Способ лечения красного плоского лишая
WO2015023226A1 (en) Use of a composition comprising chitosan and a negatively charge polysaccharide for the treament of salivary dysfuntion
US20160325012A1 (en) Gel-forming agent comprising sulfa agent and chitosan agent and having powdered dosage form
TWI862350B (zh) 治療表皮分解性水疱症的方法
WO2020053783A1 (en) A composition for use in the prevention and/or treatment of epistaxis
WO2025129601A1 (en) Method for treating epidermolysis bullosa
EP2908911A1 (en) Compositions comprising a silver salt of sucrose octasulfate and a potassium salt of sucrose octasulfate for protection of mucosal epithelia
WO2006022536A1 (en) New medical use of the meldonium
Stuchell et al. Medical management of non-neoplastic salivary gland disease
JP2688733B2 (ja) 消化管粘膜障害の予防及び治療剤

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period